(HealthDay News) -- New research finds that the targeted cancer drug Tarceva nearly triples the amount of time lung cancer patients survive without a recurrence and has fewer side effects than standard chemotherapy.
The authors of a study appearing in the July 21 online issue of The Lancet Oncology recommend using Tarceva (erlotinib) as a first-line treatment for patients with advanced non-small-cell lung cancer who have the particular gene mutation this drug targets.
Other experts agreed.
"This is a very important study [because] it shows that we can identify patients with a specific genetic marker and direct specific treatment toward them," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. Read more...
AyurGold for Healthy Blood
Showing posts with label Tarceva Battles Lung Cancer in Some. Show all posts
Showing posts with label Tarceva Battles Lung Cancer in Some. Show all posts
Tuesday, March 20, 2012
Subscribe to:
Posts (Atom)